Since LAM is caused by TSC2 or TSC1 mutations that result in overactivation of the mechanistic target of rapamycin pathway (mTOR), sirolimus (an mTOR inhibitor) has been approved for the treatment of LAM in many countries [14]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.